124 related articles for article (PubMed ID: 20831492)
1. Prediction of residual metabolic activity after treatment in NSCLC patients.
Velazquez ER; Aerts HJ; Oberije C; De Ruysscher D; Lambin P
Acta Oncol; 2010 Oct; 49(7):1033-9. PubMed ID: 20831492
[TBL] [Abstract][Full Text] [Related]
2. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
[TBL] [Abstract][Full Text] [Related]
3. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan.
Aerts HJ; van Baardwijk AA; Petit SF; Offermann C; Loon Jv; Houben R; Dingemans AM; Wanders R; Boersma L; Borger J; Bootsma G; Geraedts W; Pitz C; Simons J; Wouters BG; Oellers M; Lambin P; Bosmans G; Dekker AL; De Ruysscher D
Radiother Oncol; 2009 Jun; 91(3):386-92. PubMed ID: 19329207
[TBL] [Abstract][Full Text] [Related]
4. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer.
Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1432-41. PubMed ID: 16125870
[TBL] [Abstract][Full Text] [Related]
5. [Impact of computed tomography (CT) and 18F-deoxyglucose-coincidence detection emission tomography (FDG-CDET) image fusion for optimisation of conformal radiotherapy in non-small-cell lung cancers].
Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
Cancer Radiother; 2005 Sep; 9(5):304-15. PubMed ID: 16087377
[TBL] [Abstract][Full Text] [Related]
6. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer.
Kong FM; Frey KA; Quint LE; Ten Haken RK; Hayman JA; Kessler M; Chetty IJ; Normolle D; Eisbruch A; Lawrence TS
J Clin Oncol; 2007 Jul; 25(21):3116-23. PubMed ID: 17634490
[TBL] [Abstract][Full Text] [Related]
8. Large decreases in standardized uptake values after definitive radiation are associated with better survival of patients with locally advanced non-small cell lung cancer.
Lopez Guerra JL; Gladish G; Komaki R; Gomez D; Zhuang Y; Liao Z
J Nucl Med; 2012 Feb; 53(2):225-33. PubMed ID: 22241911
[TBL] [Abstract][Full Text] [Related]
9. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?
Gillham C; Zips D; Pönisch F; Evers C; Enghardt W; Abolmaali N; Zöphel K; Appold S; Hölscher T; Steinbach J; Kotzerke J; Herrmann T; Baumann M
Radiother Oncol; 2008 Sep; 88(3):335-41. PubMed ID: 18514339
[TBL] [Abstract][Full Text] [Related]
10. CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment.
Vahdat S; Oermann EK; Collins SP; Yu X; Abedalthagafi M; Debrito P; Suy S; Yousefi S; Gutierrez CJ; Chang T; Banovac F; Anderson ED; Esposito G; Collins BT
J Hematol Oncol; 2010 Feb; 3():6. PubMed ID: 20132557
[TBL] [Abstract][Full Text] [Related]
11. Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer.
Kaira K; Endo M; Asakura K; Tsuya A; Nakamura Y; Naito T; Murakami H; Takahashi T; Yamamoto N
Ann Nucl Med; 2010 Dec; 24(10):697-705. PubMed ID: 20824397
[TBL] [Abstract][Full Text] [Related]
12. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer.
Ashamalla H; Rafla S; Parikh K; Mokhtar B; Goswami G; Kambam S; Abdel-Dayem H; Guirguis A; Ross P; Evola A
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1016-23. PubMed ID: 15979817
[TBL] [Abstract][Full Text] [Related]
13. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study.
van Der Wel A; Nijsten S; Hochstenbag M; Lamers R; Boersma L; Wanders R; Lutgens L; Zimny M; Bentzen SM; Wouters B; Lambin P; De Ruysscher D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):649-55. PubMed ID: 15708242
[TBL] [Abstract][Full Text] [Related]
14. [Impact of PET/CT on precise radiotherapy planning for non-small cell lung cancer].
Gong HY; Yu JM; Fu Z; Li BS; Li JB; Liu TH
Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):54-7. PubMed ID: 16737623
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic value of (18)F-fluorodeoxyglucose uptake in patients with non-small cell lung cancer treated by concurrent chemoradiotherapy].
Zhang HQ; Yu JM; Meng X; Yue JB; Feng R; Ma L
Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):603-6. PubMed ID: 21122413
[TBL] [Abstract][Full Text] [Related]
16. Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: a prospective validation.
Aerts HJ; Bussink J; Oyen WJ; van Elmpt W; Folgering AM; Emans D; Velders M; Lambin P; De Ruysscher D
Lung Cancer; 2012 Jan; 75(1):73-6. PubMed ID: 21782272
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.
Hoang JK; Hoagland LF; Coleman RE; Coan AD; Herndon JE; Patz EF
J Clin Oncol; 2008 Mar; 26(9):1459-64. PubMed ID: 18349396
[TBL] [Abstract][Full Text] [Related]
18. Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer.
Kong FS; Li L; Wang W; Campbell J; Waller JL; Piert M; Gross M; Cheng M; Owen D; Stenmark M; Huang KC; Frey KA; Ten Haken RK; Lawrence TS
Radiother Oncol; 2019 Mar; 132():241-249. PubMed ID: 30389239
[TBL] [Abstract][Full Text] [Related]
19. High rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose-positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer.
Everitt S; Herschtal A; Callahan J; Plumridge N; Ball D; Kron T; Schneider-Kolsky M; Binns D; Hicks RJ; MacManus M
Cancer; 2010 Nov; 116(21):5030-7. PubMed ID: 20623786
[TBL] [Abstract][Full Text] [Related]
20. A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy.
Henderson MA; Hoopes DJ; Fletcher JW; Lin PF; Tann M; Yiannoutsos CT; Williams MD; Fakiris AJ; McGarry RC; Timmerman RD
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):789-95. PubMed ID: 19473777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
